Enhancing Oral Absorption of β-Lapachone: Progress Till Date

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 42, Issue 1, 2017, Pages 1-10

  Bermejo, Marival ^a   Mangas Sanjuan, Victor ^a   Gonzalez Alvarez, Isabel ^a   Gonzalez Alvarez, Marta ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LAPACHONE; CYCLODEXTRIN; POLYMER; BETA-LAPACHONE; DRUG CARRIER; NAPHTHOQUINONE; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANTIANGIOGENIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOSTASIS; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ADMINISTRATION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SOLUBILITY; HUMAN; HYDROGEL; MEMBRANE MICROPARTICLE; MICELLE; NONHUMAN; PHYSICAL CHEMISTRY; ANIMAL; BIOAVAILABILITY; CHEMISTRY; INTESTINE ABSORPTION; METABOLISM; ORAL DRUG ADMINISTRATION; SKIN ABSORPTION; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANIMALS; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; DRUG CARRIERS; HUMANS; INTESTINAL ABSORPTION; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; POLYMERS; SUBCUTANEOUS ABSORPTION;

EID: 84982252692     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-016-0369-7     Document Type: Article

References (71)

1. Dahan A, Lennernas H, Amidon GL. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm. 2012;9(6):1847–51. doi:10.1021/mp300140h.
2. Lind C, Cadenas E, Hochstein P, Ernster L. DT-diaphorase: purification, properties, and function. Methods Enzymol. 1990;186:287–301.
3. Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 2012;83(8):1033–40. doi:10.1016/j.bcp.2011.12.017.
4. Glen VL, Hutson PR, Kehrli NJ, Boothman DA, Wilding G. Quantitation of beta-lapachone and 3-hydroxy-beta-lapachone in human plasma samples by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1997;692(1):181–6.
5. Bey EA, Reinicke KE, Srougi MC, Varnes M, Anderson VE, Pink JJ, et al. Catalase abrogates beta-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers. Mol Cancer Ther. 2013;12(10):2110–20. doi:10.1158/1535-7163.MCT-12-0962.
6. Chakrabarti G, Silvers MA, Ilcheva M, Liu Y, Moore ZR, Luo X, et al. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, beta-lapachone. Sci Rep. 2015;5:17066. doi:10.1038/srep17066.
7. Woo HJ, Choi YH. Growth inhibition of A549 human lung carcinoma cells by beta-lapachone through induction of apoptosis and inhibition of telomerase activity. Int J Oncol. 2005;26(4):1017–23.
8. Ma J, Lim C, Sacher JR, Van Houten B, Qian W, Wipf P. Mitochondrial targeted beta-lapachone induces mitochondrial dysfunction and catastrophic vacuolization in cancer cells. Bioorg Med Chem Lett. 2015;25(21):4828–33. doi:10.1016/j.bmcl.2015.06.073.
9. Menacho-Marquez M, Rodriguez-Hernandez CJ, Villaronga MA, Perez-Valle J, Gadea J, Belandia B, et al. eIF2 kinases mediate beta-lapachone toxicity in yeast and human cancer cells. Cell Cycle. 2015;14(4):630–40. doi:10.4161/15384101.2014.994904.
10. Winski SL, Koutalos Y, Bentley DL, Ross D. Subcellular localization of NAD(P)H:quinone oxidoreductase 1 in human cancer cells. Cancer Res. 2002;62(5):1420–4.
11. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med. 2000;29(3–4):246–53.
12. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res. 1998;4(9):2065–70.
13. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharmacol. 1991;42(5):1021–7.
14. Strassburg A, Strassburg CP, Manns MP, Tukey RH. Differential gene expression of NAD(P)H:quinone oxidoreductase and NRH:quinone oxidoreductase in human hepatocellular and biliary tissue. Mol Pharmacol. 2002;61(2):320–5.
15. Schlager JJ, Powis G. Cytosolic NAD(P)H:(quinone-acceptor)oxidoreductase in human normal and tumor tissue: effects of cigarette smoking and alcohol. Int J Cancer. 1990;45(3):403–9.
16. Schor NA, Morris HP. The activity of the D-T diaphorase in experimental hepatomas. Cancer Biochem Biophys. 1977;2(1):5–9.
17. Dolan ME, Frydman B, Thompson CB, Diamond AM, Garbiras BJ, Safa AR, et al. Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents. Anticancer Drugs. 1998;9(5):437–48.
18. Frydman B, Marton LJ, Sun JS, Neder K, Witiak DT, Liu AA, et al. Induction of DNA topoisomerase II-mediated DNA cleavage by beta-lapachone and related naphthoquinones. Cancer Res. 1997;57(4):620–7.
19. Li CJ, Averboukh L, Pardee AB. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. J Biol Chem. 1993;268(30):22463–8.
20. Li CJ, Wang C, Pardee AB. Induction of apoptosis by beta-lapachone in human prostate cancer cells. Cancer Res. 1995;55(17):3712–5.
21. Li YZ, Li CJ, Pinto AV, Pardee AB. Release of mitochondrial cytochrome C in both apoptosis and necrosis induced by beta-lapachone in human carcinoma cells. Mol Med. 1999;5(4):232–9.
22. Pardee AB, Li YZ, Li CJ. Cancer therapy with beta-lapachone. Curr Cancer Drug Targets. 2002;2(3):227–42.
23. Planchon SM, Wuerzberger S, Frydman B, Witiak DT, Hutson P, Church DR, et al. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer Res. 1995;55(17):3706–11.
24. Samali A, Nordgren H, Zhivotovsky B, Peterson E, Orrenius S. A comparative study of apoptosis and necrosis in HepG2 cells: oxidant-induced caspase inactivation leads to necrosis. Biochem Biophys Res Commun. 1999;255(1):6–11. doi:10.1006/bbrc.1998.0139.
25. Li JZ, Ke Y, Misra HP, Trush MA, Li YR, Zhu H, et al. Mechanistic studies of cancer cell mitochondria- and NQO1-mediated redox activation of beta-lapachone, a potentially novel anticancer agent. Toxicol Appl Pharmacol. 2014;281(3):285–93. doi:10.1016/j.taap.2014.10.012.
26. Park EJ, Min KJ, Lee TJ, Yoo YH, Kim YS, Kwon TK. beta-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells. Cell Death Dis. 2014;5:e1230. doi:10.1038/cddis.2014.202.
27. Awadallah NS, Dehn D, Shah RJ, Russell Nash S, Chen YK, Ross D, et al. NQO1 expression in pancreatic cancer and its potential use as a biomarker. Appl Immunohistochem Mol Morphol. 2008;16(1):24–31. doi:10.1097/PAI.0b013e31802e91d0.
28. Jeon YJ, Bang W, Choi YH, Shim JH, Chae JI. Beta-lapachone suppresses non-small cell lung cancer proliferation through the regulation of specificity protein 1. Biol Pharm Bull. 2015;38(9):1302–8. doi:10.1248/bpb.b15-00159.
29. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumor xenografts to mitomycin Cl. Cancer Res. 1992;52(17):4752–7.
30. Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, et al. Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by ss-lapachone. Cancer Metab. 2015;3:12. doi:10.1186/s40170-015-0137-1.
31. Di Rosso ME, Barreiro Arcos ML, Elingold I, Sterle H, Baptista Ferreira S, Ferreira VF, et al. Novel o-naphthoquinones induce apoptosis of EL-4 T lymphoma cells through the increase of reactive oxygen species. Toxicol In Vitro. 2013;27(7):2094–104. doi:10.1016/j.tiv.2013.08.002.
32. Moon DO, Choi YH, Kim ND, Park YM, Kim GY. Anti-inflammatory effects of beta-lapachone in lipopolysaccharide-stimulated BV2 microglia. Int Immunopharmacol. 2007;7(4):506–14. doi:10.1016/j.intimp.2006.12.006.
33. Yu HY, Kim SO, Jin CY, Kim GY, Kim WJ, Yoo YH, et al. beta-Lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K/Akt pathway. Biomol Ther (Seoul). 2014;22(3):184–92. doi:10.4062/biomolther.2014.026.
34. Aires Ade L, Ximenes EC, Barbosa VX, Goes AJ, Souza VM, Albuquerque MC. beta-Lapachone: a naphthoquinone with promising antischistosomal properties in mice. Phytomedicine. 2014;21(3):261–7. doi:10.1016/j.phymed.2013.08.012.
35. Mata-Santos T, Pinto NF, Mata-Santos HA, De Moura KG, Carneiro PF, Carvalho Tdos S, et al. Anthelmintic activity of lapachol, beta-lapachone and its derivatives against Toxocara Canis Larvae. Rev Inst Med Trop Sao Paulo. 2015;57(3):197–204. doi:10.1590/S0036-46652015000300003.
36. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arner ES, et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 2007;4(6):e206. doi:10.1371/journal.pmed.0040206.
37. Mohamed AM, Metwally NM, Mahmoud SS. Sativa seeds against Schistosoma mansoni different stages. Mem Inst Oswaldo Cruz. 2005;100(2):205–11. doi:10.1590/S0074-02762005000200016
38. Seif el-Din SH, Al-Hroob AM, Ebeid FA. Schistosoma mansoni: N-acetylcysteine downregulates oxidative stress and enhances the antischistosomal activity of artemether in mice. Exp Parasitol. 2011;128(3):230–5. doi:10.1016/j.exppara.2011.03.006.
39. Park SW, Kim JH, Kim KE, Jeong MH, Park H, Park B, et al. Beta-lapachone inhibits pathological retinal neovascularization in oxygen-induced retinopathy via regulation of HIF-1alpha. J Cell Mol Med. 2014;18(5):875–84. doi:10.1111/jcmm.12235.
40. Kim YH, Hwang JH, Kim KS, Noh JR, Gang GT, Kim SW, et al. NQO1 activation regulates angiotensin-converting enzyme shedding in spontaneously hypertensive rats. Cardiovasc Res. 2013;99(4):743–50. doi:10.1093/cvr/cvt147.
41. de Castro SL, Emery FS, da Silva Junior EN. Synthesis of quinoidal molecules: strategies towards bioactive compounds with an emphasis on lapachones. Eur J Med Chem. 2013;69:678–700. doi:10.1016/j.ejmech.2013.07.057.
42. Ough M, Lewis A, Bey EA, Gao J, Ritchie JM, Bornmann W, et al. Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biol Ther. 2005;4(1):95–102.
43. Nasongkla N, Wiedmann AF, Bruening A, Beman M, Ray D, Bornmann WG, et al. Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. Pharm Res. 2003;20(10):1626–33.
44. Kim I, Kim H, Ro J, Jo K, Karki S, Khadka P, et al. Preclinical pharmacokinetic evaluation of beta-lapachone: characteristics of oral bioavailability and first-pass metabolism in rats. Biomol Ther (Seoul). 2015;23(3):296–300. doi:10.4062/biomolther.2015.029.
45. Li X, Bian J, Wang N, Qian X, Gu J, Mu T, et al. Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: design, synthesis, and in vivo antitumor evaluation. Bioorg Med Chem. 2016;24(5):1006–13. doi:10.1016/j.bmc.2016.01.024.
46. https://disco.chemaxon.com/apps/demos/logd/. 2016.
47. Blanco E, Bey EA, Khemtong C, Yang SG, Setti-Guthi J, Chen H, et al. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. Cancer Res. 2010;70(10):3896–904. doi:10.1158/0008-5472.CAN-09-3995.
48. Mangas-Sanjuan V, Gutierrez-Nieto J, Echezarreta-Lopez M, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Casabo VG, et al. Intestinal permeability of beta-lapachone and its cyclodextrin complexes and physical mixtures. Eur J Drug Metab Pharmacokinet. 2015;. doi:10.1007/s13318-015-0310-5.
49. Sanchez-Castano G, Ruiz-Garcia A, Banon N, Bermejo M, Merino V, Freixas J, et al. Intrinsic absolute bioavailability prediction in rats based on in situ absorption rate constants and/or in vitro partition coefficients: 6-fluoroquinolones. J Pharm Sci. 2000;89(11):1395–403.
50. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther. 1997;283(1):46–58.
51. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health. 1997;13(4):407–84.
52. Gomez Castellanos JR, Prieto JM, Heinrich M. Red Lapacho (Tabebuia impetiginosa)–a global ethnopharmacological commodity? J Ethnopharmacol. 2009;121(1):1–13. doi:10.1016/j.jep.2008.10.004.
53. Queiroz ML, Valadares MC, Torello CO, Ramos AL, Oliveira AB, Rocha FD, et al. Comparative studies of the effects of Tabebuia avellanedae bark extract and beta-lapachone on the hematopoietic response of tumour-bearing mice. J Ethnopharmacol. 2008;117(2):228–35. doi:10.1016/j.jep.2008.01.034.
54. Cook AJ, Tuchili LM, Buve A, Foster SD, Godfrey-Fausett P, Pandey GS, et al. Human and bovine tuberculosis in the Monze District of Zambia–a cross-sectional study. Br Vet J. 1996;152(1):37–46.
55. Cunha-Filho MS, Martinez-Pacheco R, Landin M. Compatibility of the antitumoral beta-lapachone with different solid dosage forms excipients. J Pharm Biomed Anal. 2007;45(4):590–8. doi:10.1016/j.jpba.2007.08.016.
56. Dahan A, Miller JM. The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs. Aaps J. 2012;14(2):244–51. doi:10.1208/s12248-012-9337-6.
57. Jang SB, Kim D, Kim SY, Park C, Jeong JH, Kuh HJ, et al. Impact of micellar vehicles on in situ intestinal absorption properties of beta-lapachone in rats. Korean J Physiol Pharmacol. 2013;17(1):9–13. doi:10.4196/kjpp.2013.17.1.9.
58. Masaoka Y, Tanaka Y, Kataoka M, Sakuma S, Yamashita S. Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci. 2006;29(3–4):240–50. doi:10.1016/j.ejps.2006.06.004.
59. Lozoya-Agullo I, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Merino-Sanjuan M, Bermejo M. In situ perfusion model in rat colon for drug absorption studies: comparison with small intestine and Caco-2 cell model. J Pharm Sci. 2015;104(9):3136–45. doi:10.1002/jps.24447.
60. Cunha-Filho MS, Alvarez-Lorenzo C, Martinez-Pacheco R, Landin M. Temperature-sensitive gels for intratumoral delivery of beta-lapachone: effect of cyclodextrins and ethanol. ScientificWorldJournal. 2012;2012:126723. doi:10.1100/2012/126723.
61. Cavalcanti IM, Mendonca EA, Lira MC, Honrato SB, Camara CA, Amorim RV, et al. The encapsulation of beta-lapachone in 2-hydroxypropyl-beta-cyclodextrin inclusion complex into liposomes: a physicochemical evaluation and molecular modeling approach. Eur J Pharm Sci. 2011;44(3):332–40. doi:10.1016/j.ejps.2011.08.011.
62. Sjoberg A, Lutz M, Tannergren C, Wingolf C, Borde A, Ungell AL. Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique. Eur J Pharm Sci. 2013;48(1–2):166–80. doi:10.1016/j.ejps.2012.10.007.
63. Cunha-Filho MS, Martinez-Pacheco R, Landin M. Dissolution rate enhancement of the novel antitumoral beta-lapachone by solvent change precipitation of microparticles. Eur J Pharm Biopharm. 2008;69(3):871–7. doi:10.1016/j.ejpb.2008.02.014.
64. Miyazaki S, Yokouchi C, Nakamura T, Hashiguchi N, Hou WM, Takada M. Pluronic F-127 gels as a novel vehicle for rectal administration of indomethacin. Chem Pharm Bull (Tokyo). 1986;34(4):1801–8.
65. Fawaz F, Koffi A, Guyot M, Millet P. Comparative in vitro-in vivo study of two quinine rectal gel formulations. Int J Pharm. 2004;280(1–2):151–62. doi:10.1016/j.ijpharm.2004.05.002.
66. Choi WH, Ahn J, Jung CH, Jang YJ, Ha TY. Beta-lapachone prevents diet-induced obesity by increasing energy expenditure and stimulating the browning of white adipose tissue via down-regulation of miR-382 expression. Diabetes. 2016;. doi:10.2337/db15-1423.
67. Wang F, Blanco E, Ai H, Boothman DA, Gao J. Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation. J Pharm Sci. 2006;95(10):2309–19. doi:10.1002/jps.20721.
68. Reinicke KE, Bey EA, Bentle MS, Pink JJ, Ingalls ST, Hoppel CL, et al. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels. Clin Cancer Res. 2005;11(8):3055–64. doi:10.1158/1078-0432.CCR-04-2185.
69. Ma X, Huang X, Huang G, Li L, Wang Y, Luo X, et al. Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of beta-Lapachone. Adv Healthc Mater. 2014;3(8):1210–6. doi:10.1002/adhm.201300590.
70. Savage RE, Tyler AN, Miao XS, Chan TC. Identification of a novel glucosylsulfate conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (ARQ 501, beta-lapachone) in mammals. Drug Metab Dispos. 2008;36(4):753–8. doi:10.1124/dmd.107.018655.
71. Seoane S, Diaz-Rodriguez P, Sendon-Lago J, Gallego R, Perez-Fernandez R, Landin M. Administration of the optimized beta-Lapachone-poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model. Eur J Pharm Biopharm. 2013;84(3):497–504. doi:10.1016/j.ejpb.2012.12.019.